Unknown

Dataset Information

0

Evaluation of the cytotoxic and immunogenic potential of temozolamide, panobinostat, and Lophophora williamsii extract against C6 glioma cells.


ABSTRACT: Glioblastoma multiforme is a malignant neoplasm of the brain with poor prognosis. The first-line drug against glioblastoma is the alkylating agent temozolamide (TMZ); unfortunately, treatment resistance and tumor re-incidence are common. In some cases, immunogenic cell death (ICD) inducers can decrease treatment resistance and tumor recurrence by stimulating an antitumor specific immune response. Not all ICD inducers, however, are suitable for glioma patients because of the low permeability of the blood-brain barrier (BBB). Panobinostat (PAN), a histone deacetylase inhibitor and Lophophora williamsii (LW) extract can pass through the BBB and have antitumor properties. The aim of this study is to evaluate the cytotoxic potential of TMZ, PAN and LW extract against the glioma C6 cell line, and its role in the release of damage-associated molecular patterns (DAMPs), which is a hallmark of ICD. Our results indicate that all treatments induce cellular death in a time- and concentration-dependent manner, and that PAN and LW extract induce apoptosis, whereas TMZ induces apoptosis and necrosis. Also, that some of the treatments and their sequential administration induce the release of DAMPs. Furthermore, in a rat glioma model, we observed that all treatments decreased tumor volume, but the in vivo cell death mechanism was not ICD. Our findings indicate that TMZ, PAN, and LW combination have a cytotoxic effect against glioma cells but do not induce ICD.

SUBMITTER: Franco-Molina MA 

PROVIDER: S-EPMC8056056 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evaluation of the cytotoxic and immunogenic potential of temozolamide, panobinostat, and <i>Lophophora williamsii</i> extract against C6 glioma cells.

Franco-Molina Moisés Armides MA   Santana-Krímskaya Silvia Elena SE   Madrigal-de-León Luis Mario LM   Coronado-Cerda Erika Evangelina EE   Zárate-Triviño Diana Ginette DG   Hernández-Martínez Sara Paola SP   García-Coronado Paola Leonor PL   Rodríguez-Padilla Cristina C  

EXCLI journal 20210309


Glioblastoma multiforme is a malignant neoplasm of the brain with poor prognosis. The first-line drug against glioblastoma is the alkylating agent temozolamide (TMZ); unfortunately, treatment resistance and tumor re-incidence are common. In some cases, immunogenic cell death (ICD) inducers can decrease treatment resistance and tumor recurrence by stimulating an antitumor specific immune response. Not all ICD inducers, however, are suitable for glioma patients because of the low permeability of t  ...[more]

Similar Datasets

| S-EPMC5525900 | biostudies-other
| S-EPMC5563692 | biostudies-literature
| S-EPMC10458490 | biostudies-literature
| S-EPMC3335089 | biostudies-literature
| S-EPMC6099735 | biostudies-literature
| S-EPMC7662631 | biostudies-literature
| S-EPMC9785660 | biostudies-literature
| S-EPMC7498526 | biostudies-literature
| S-EPMC9412540 | biostudies-literature
| S-EPMC10525758 | biostudies-literature